These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21398121)

  • 21. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors.
    Escribano A; Mateo AI; Martin de la Nava EM; Mayhugh DR; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel AG; Sweetana SA; Cannady EA; Mantlo NB
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3671-5. PubMed ID: 22543028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.
    Wang A; Prouty CP; Pelton PD; Yong M; Demarest KT; Murray WV; Kuo GH
    Bioorg Med Chem Lett; 2010 Feb; 20(4):1432-5. PubMed ID: 20089400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk.
    Mantlo NB; Escribano A
    J Med Chem; 2014 Jan; 57(1):1-17. PubMed ID: 23941686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors.
    Wang Y; Yang W; Finlay HJ; Harikrishnan LS; Jiang J; Kamau MG; Van Kirk K; Nirschl DS; Taylor DS; Chen AY; Yin X; Sleph PG; Yang RZ; Huang CS; Adam LP; Lawrence RM; Wexler RR; Salvati ME
    Bioorg Med Chem Lett; 2014 Feb; 24(3):860-4. PubMed ID: 24424134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel tetrahydrochinoline derived CETP inhibitors.
    Schmeck C; Gielen-Haertwig H; Vakalopoulos A; Bischoff H; Li V; Wirtz G; Weber O
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1740-3. PubMed ID: 20137927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors.
    Harikrishnan LS; Finlay HJ; Qiao JX; Kamau MG; Jiang J; Wang TC; Li J; Cooper CB; Poss MA; Adam LP; Taylor DS; Chen AY; Yin X; Sleph PG; Yang RZ; Sitkoff DF; Galella MA; Nirschl DS; Van Kirk K; Miller AV; Huang CS; Chang M; Chen XQ; Salvati ME; Wexler RR; Lawrence RM
    J Med Chem; 2012 Jul; 55(13):6162-75. PubMed ID: 22650305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of a novel class of biphenyl CETP inhibitors.
    Lu Z; Napolitano JB; Theberge A; Ali A; Hammond ML; Tan E; Tong X; Xu SS; Latham MJ; Peterson LB; Anderson MS; Eveland SS; Guo Q; Hyland SA; Milot DP; Chen Y; Sparrow CP; Wright SD; Sinclair PJ
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7469-72. PubMed ID: 21041082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel benzoxazole inhibitors of mPGES-1.
    Kablaoui N; Patel S; Shao J; Demian D; Hoffmaster K; Berlioz F; Vazquez ML; Moore WM; Nugent RA
    Bioorg Med Chem Lett; 2013 Feb; 23(3):907-11. PubMed ID: 23266122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triazoloamides as potent γ-secretase modulators with reduced hERG liability.
    Fischer C; Zultanski SL; Zhou H; Methot JL; Shah S; Nuthall H; Hughes BL; Smotrov N; Hill A; Szewczak AA; Moxham CM; Bays N; Middleton RE; Munoz B; Shearman MS
    Bioorg Med Chem Lett; 2012 May; 22(9):3140-6. PubMed ID: 22497762
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
    Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CETP inhibition in cardiovascular risk management: a critical appraisal.
    Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
    Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).
    Qiao JX; Wang TC; Adam LP; Chen AY; Taylor DS; Yang RZ; Zhuang S; Sleph PG; Li JP; Li D; Yin X; Chang M; Chen XQ; Shen H; Li J; Smith D; Wu DR; Leith L; Harikrishnan LS; Kamau MG; Miller MM; Bilder D; Rampulla R; Li YX; Xu C; Lawrence RM; Poss MA; Levesque P; Gordon DA; Huang CS; Finlay HJ; Wexler RR; Salvati ME
    J Med Chem; 2015 Nov; 58(22):9010-26. PubMed ID: 26524347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2D Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors.
    Castilho MS; Guido RV; Andricopulo AD
    Bioorg Med Chem; 2007 Sep; 15(18):6242-52. PubMed ID: 17604633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells.
    Huang Z; Inazu A; Kawashiri MA; Nohara A; Higashikata T; Mabuchi H
    Am J Physiol Endocrinol Metab; 2003 Jun; 284(6):E1210-9. PubMed ID: 12604506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.